Accuracy of New John Cunningham Virus Antibody Assay in Natalizumab-Treated Patients With Multiple Sclerosis.
作者信息
Gelissen Liza M Y, Wijburg Martijn T, Strijbis Eva M M, van Oosten Bob W, de Jong Brigit A, Uitdehaag Bernard M J, Rispens Theo, Feltkamp Mariet C W, van Kempen Zoé L E, Killestein Joep
机构信息
MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam University Medical Center (UMC) location Boelelaan, Amsterdam, the Netherlands.
Research and Lab Services Department, Sanquin Blood Supply, Amsterdam, the Netherlands.
出版信息
JAMA Neurol. 2025 May 1;82(5):523-525. doi: 10.1001/jamaneurol.2025.0337.
Abstract
摘要
相似文献
1
Accuracy of New John Cunningham Virus Antibody Assay in Natalizumab-Treated Patients With Multiple Sclerosis.新型约翰·坎宁安病毒抗体检测在那他珠单抗治疗的多发性硬化症患者中的准确性
JAMA Neurol. 2025 May 1;82(5):523-525. doi: 10.1001/jamaneurol.2025.0337.
2
Association of B-cell activating factor gene variants with serum anti-JCV antibody positivity in male patients with multiple sclerosis under natalizumab treatment: Implications for progressive multifocal leukoencephalopathy risk stratification.在接受那他珠单抗治疗的多发性硬化男性患者中，B 细胞激活因子基因变异与血清抗 JCV 抗体阳性的相关性：对进行性多灶性白质脑病风险分层的影响。
J Neurol Sci. 2024 Jun 15;461:123046. doi: 10.1016/j.jns.2024.123046. Epub 2024 May 12.
3
Systematic review of the published data on the worldwide prevalence of John Cunningham virus in patients with multiple sclerosis and neuromyelitis optica.对全球多发性硬化症和视神经脊髓炎患者中约翰·坎宁安病毒流行率已发表数据的系统评价。
Epidemiol Health. 2018 Jan 5;40:e2018001. doi: 10.4178/epih.e2018001. eCollection 2018.
4
Evaluating the efficacy and safety of transitioning patients with multiple sclerosis from natalizumab to ocrelizumab (OCTAVE).评估多发性硬化症患者从那他珠单抗转换为奥瑞珠单抗的疗效和安全性（OCTAVE研究）。
Mult Scler. 2023 Jul;29(8):956-966. doi: 10.1177/13524585231175284. Epub 2023 Jun 15.
5
John Cunningham Virus Status, Seroconversion Rate, and the Risk of Progressive Multifocal Leukoencephalopathy in Polish John Cunningham Virus-Seronegative Patients with Relapsing-Remitting Multiple Sclerosis.波兰复发性缓解型多发性硬化症约翰·坎宁安病毒血清阴性患者的约翰·坎宁安病毒状态、血清转化率和进行性多灶性白质脑病风险。
Eur Neurol. 2020;83(5):487-492. doi: 10.1159/000510849. Epub 2020 Oct 7.
6
Natalizumab for relapsing remitting multiple sclerosis.那他珠单抗用于复发缓解型多发性硬化症。
Cochrane Database Syst Rev. 2011 Oct 5(10):CD007621. doi: 10.1002/14651858.CD007621.pub2.
7
Natalizumab for induction of remission in Crohn's disease.那他珠单抗用于诱导克罗恩病缓解
Cochrane Database Syst Rev. 2006 Jul 19(3):CD006097. doi: 10.1002/14651858.CD006097.
8
Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.在那他珠单抗相关的进行性多灶性白质脑病之前，对多发性硬化症患者进行的纵向JCV血清学研究。
Mult Scler. 2015 Oct;21(12):1600-3. doi: 10.1177/1352458514567728. Epub 2015 Feb 6.
9
Natalizumab for induction of remission in Crohn's disease.那他珠单抗用于诱导克罗恩病缓解
Cochrane Database Syst Rev. 2007 Jan 24(1):CD006097. doi: 10.1002/14651858.CD006097.pub2.
10
Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study).依那西普治疗复发性多发性硬化症 24 剂后的疗效：来自意大利自发的、前瞻性和观察性研究（TY-STOP 研究）的证据。
JAMA Neurol. 2014 Aug;71(8):954-60. doi: 10.1001/jamaneurol.2014.1200.
引用本文的文献
1
Stratify and ImmunoWELL JCV tests performances in a real-world multiple sclerosis cohort: possible clinical implications of biosimilar Natalizumab use.在真实世界的多发性硬化症队列中对Stratify和ImmunoWELL JCV检测性能进行分层：生物类似药那他珠单抗使用的潜在临床意义。
J Neurol. 2025 Aug 19;272(9):583. doi: 10.1007/s00415-025-13273-z.
2
Error in the Results.结果中的错误。
JAMA Neurol. 2025 Aug 18. doi: 10.1001/jamaneurol.2025.3097.
3
Errors in the Results.结果中的错误。
JAMA Neurol. 2025 May 1;82(5):529. doi: 10.1001/jamaneurol.2025.1468.
本文引用的文献
1
Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis: The Antelope Phase 3 Randomized Clinical Trial.在复发缓解型多发性硬化症患者中评估拟生物类似药那他珠单抗（PB006）的疗效和安全性：Antelope 期 3 随机临床试验。
JAMA Neurol. 2023 Mar 1;80(3):298-307. doi: 10.1001/jamaneurol.2022.5007.
2
Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies.多发性硬化症患者使用那他珠单抗相关进行性多灶性白质脑病的风险：四项临床研究数据的回顾性分析。
Lancet Neurol. 2017 Nov;16(11):925-933. doi: 10.1016/S1474-4422(17)30282-X. Epub 2017 Sep 29.
3
A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification.用于检测人血清和血浆中 JC 病毒抗体的第二代 ELISA（STRATIFY JCV™ DxSelect™），以支持进行进行性多灶性白质脑病的风险分层。
J Clin Virol. 2013 Jun;57(2):141-6. doi: 10.1016/j.jcv.2013.02.002. Epub 2013 Mar 5.
4
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.那他珠单抗治疗复发型多发性硬化症的随机安慰剂对照试验。
N Engl J Med. 2006 Mar 2;354(9):899-910. doi: 10.1056/NEJMoa044397.
Zotero 插件